Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Smallridge RC, Chindris AM, Asmann YW, Casler JD, Serie DJ, Reddi HV, Cradic KW, Rivera M, Grebe SK, Necela BM, Eberhardt NL, Carr JM, McIver B, Copland JA, Thompson EA.

J Clin Endocrinol Metab. 2014 Feb;99(2):E338-47. doi: 10.1210/jc.2013-2792.

2.

BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.

Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D.

J Clin Endocrinol Metab. 2007 Jul;92(7):2840-3.

PMID:
17488796
3.

BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.

Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL.

Thyroid. 2014 Sep;24(9):1385-93. doi: 10.1089/thy.2014.0134.

4.

Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.

Oler G, Camacho CP, Hojaij FC, Michaluart P Jr, Riggins GJ, Cerutti JM.

Clin Cancer Res. 2008 Aug 1;14(15):4735-42. doi: 10.1158/1078-0432.CCR-07-4372.

5.

Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.

Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, Ye C, Chen L.

Eur J Endocrinol. 2013 Apr 15;168(5):675-81. doi: 10.1530/EJE-12-1029.

6.

TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.

Zou M, Baitei EY, Al-Rijjal RA, Parhar RS, Al-Mohanna FA, Kimura S, Pritchard C, Binessa HA, Alzahrani AS, Al-Khalaf HH, Hawwari A, Akhtar M, Assiri AM, Meyer BF, Shi Y.

Oncogene. 2016 Apr 14;35(15):1909-18. doi: 10.1038/onc.2015.253.

PMID:
26477313
7.

BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.

Bastos AU, Oler G, Nozima BH, Moysés RA, Cerutti JM.

Eur J Endocrinol. 2015 Oct;173(4):525-40. doi: 10.1530/EJE-15-0254.

8.

BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.

Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V.

Mod Pathol. 2010 Aug;23(8):1052-60. doi: 10.1038/modpathol.2010.86.

9.

Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.

Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N.

Mol Cancer Ther. 2007 Mar;6(3):1070-8.

10.

BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation.

Virk RK, Van Dyke AL, Finkelstein A, Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa JA, Udelsman R, Prasad ML.

Mod Pathol. 2013 Jan;26(1):62-70. doi: 10.1038/modpathol.2012.152.

11.

In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.

Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, De Vito C, Calvanese A, Palermo S, Persechino S, De Antoni E, D'Armiento M.

Clin Endocrinol (Oxf). 2012 Nov;77(5):780-6. doi: 10.1111/j.1365-2265.2012.04465.x.

PMID:
22702340
12.

BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H.

Endocrine. 2012 Oct;42(2):404-10.

PMID:
22426956
13.

BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study.

Tallini G, de Biase D, Durante C, Acquaviva G, Bisceglia M, Bruno R, Bacchi Reggiani ML, Casadei GP, Costante G, Cremonini N, Lamartina L, Meringolo D, Nardi F, Pession A, Rhoden KJ, Ronga G, Torlontano M, Verrienti A, Visani M, Filetti S.

Mod Pathol. 2015 Oct;28(10):1343-59. doi: 10.1038/modpathol.2015.92.

14.

Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.

Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, Cohen C, Sharma J.

J Surg Res. 2013 Nov;185(1):217-24. doi: 10.1016/j.jss.2013.05.003.

15.

Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.

Khan MS, Pandith AA, Masoodi SR, Wani KA, Ul Hussain M, Mudassar S.

Endocrine. 2014 Nov;47(2):449-55. doi: 10.1007/s12020-014-0319-6.

PMID:
24927793
16.

The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.

Daliri M, Abbaszadegan MR, Bahar MM, Arabi A, Yadollahi M, Ghafari A, Taghehchian N, Zakavi SR.

Endocr Res. 2014;39(4):189-93. doi: 10.3109/07435800.2013.879169.

PMID:
24679337
17.

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.

Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34.

PMID:
18070147
18.

BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy.

Santoro A, Pannone G, Carosi MA, Francesconi A, Pescarmona E, Russo GM, Feola A, Losito S, Franco R, Nappi L, Aquino G, De Rosa G, Di Domenico M, Bufo P.

J Cell Biochem. 2013 May;114(5):1174-82. doi: 10.1002/jcb.24460.

PMID:
23192464
19.

CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas.

Torregrossa L, Giannini R, Borrelli N, Sensi E, Melillo RM, Leocata P, Materazzi G, Miccoli P, Santoro M, Basolo F.

Mod Pathol. 2012 Jan;25(1):46-55. doi: 10.1038/modpathol.2011.140.

20.

Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.

Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P.

J Clin Endocrinol Metab. 2010 Sep;95(9):4197-205. doi: 10.1210/jc.2010-0337.

PMID:
20631031
Items per page

Supplemental Content

Support Center